← board
KALA
distress 8/10 · high distress / dilution risk$0.69-6%today-100% from 52w high
Lead: persistent corneal epithelial defect (PCED)
Revenue
pre-revenue
Liquidity
$9M
Runway
0.3 yrs
Shares 1y
+165%
Price & events
-97.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-6.4%
1D
-18.5%
1W
-77.9%
1M
-91.0%
3M
-97.7%
6M
-99.8%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $12.83M
- Enterprise Value
- $38.01M
- Volume
- 43.23K
- 52 Week Range
- $0.69 – $982
- Total Shares
- 18.59M
- Float Shares
- 18.59M
- Short %
- 1.18%
- % Held by Insiders
- 1.29%
- % Held by Institutions
- 0.64%
- RVOL
- 0.23x
- Beta
- -2.36
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-03-03partnershipExclusive worldwide license for Researgency AI platform in biotechnology field.SEC 8-K
- 2025-11-09partnershipEntered convertible loan agreement with individual investor for up to $375,000.SEC 8-K
- 2025-10-19trial discontinuedBoard terminates all remaining employees except those needed for foreclosure.SEC 8-K
- 2025-10-18trial discontinuedLender Oxford forecloses on assets and sweeps cash.SEC 8-K
- third quarter of 2025readoutPhase 2KPI-012 · Topline data from CHASE trial.SEC 8-K
- 2025-09-29trial discontinuedKPI-012 · Company to cease development of KPI-012 and mesenchymal stem cell secretome platformSEC 8-K
- 2025-07-09enrollment completesecondaryPhase 2KPI-012 · Completed patient enrollment in CHASE Phase 2b trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-29HC Wainwright & Co.Buy → Neutral
- 2025-09-17HC Wainwright & Co.Buy
- 2025-09-11OppenheimerOutperform
- 2025-09-08MizuhoOutperform
- 2025-05-23HC Wainwright & Co.Buy
- 2025-04-04HC Wainwright & Co.Buy
Competitors — persistent corneal epithelial defect (PCED)
- none identified
Recent news
- 2026-07-02David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
- 2026-06-26KALA BIO, Inc. SEC Filing (Jun 26, 2026) - Stock Titan
- 2026-05-29KALA BIO Q4 2025 Earnings: Wider-Than-Expected Loss but Narrower EPS Surprise Drives Mixed Sentiment - Guidance Update - dars.gov.et
- 2026-05-15KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary - TradingView
- 2026-05-07Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
- 2026-05-07KALA BIO Announces Reverse Stock Split - GlobeNewswire
- 2026-05-07KALA BIO cuts share count to 18.6M in 1-for-50 reverse split - Stock Titan
- 2026-04-21Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - Investing News Network
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.